Aclara Research Leads Medical Cannabis Industry with Release of Largest Illinois Patient Study

Aclara Research Leads Medical Cannabis Industry with Release of Largest Illinois Patient Study

Study Showcases Positive Impact of Medical Cannabis among Patients and Health Care Industry

Chicago, IL - May 23, 2017 (Investorideas.com Newswire) Aclara Research, a leader in the development of patient and consumer insights within the medical cannabis industry, today released the results of The Illinois Medical Cannabis Patient Experience Study - the first of Illinois patients since the inception of the pilot program in 2012. The study is the largest and most comprehensive look at the impact of the statewide program, examining nearly 300 of the 18,000 Illinois residents registered.

The Aclara Research study found that 86 percent of survey respondents are managing leading symptoms of chronic pain. While chronic pain is not one of the 41 qualifying conditions in Illinois, cannabis shows strong potential in treating autoimmune diseases in which chronic inflammation plays a central role.

Read this news in full at http://www.investorideas.com/news/2017/marijuana/05231Illinois.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.